Mounjaro weight loss: how it works and what the evidence shows

What does Mounjaro actually do inside the body?

Most weight-loss injections work on one receptor. Mounjaro (the brand name for tirzepatide, made by Eli Lilly) works on two: the GIP receptor and the GLP-1 receptor. Both are involved in the body's appetite and blood-sugar signalling after meals. Activating them together reduces hunger more substantially than either pathway alone, slows gastric emptying so you feel full for longer, and improves insulin sensitivity.

That dual mechanism is why tirzepatide sits in a different pharmacological category from other GLP-1 medicines. The appetite reduction tends to feel gradual rather than sudden, most people notice they are leaving food on the plate before they consciously register eating less. The NHS medicines page for tirzepatide explains the mechanism and what to expect in plain language, and is worth reading before you start.

Weight is shaped by biology (hormones, genetics, environment) not willpower alone. That framing matters, because it explains why these medicines work at a physiological level rather than simply making you try harder.

What does the clinical evidence say about how much weight people lose?

The headline figures come from SURMOUNT-1, a 72-week randomised controlled trial involving 2,539 adults with obesity. Participants taking the 15mg dose lost an average of around 20–21% of their body weight. Some analyses put the figure closer to 22.5% among those who completed the full course. People taking 10mg saw average reductions of around 19%. These are trial averages, individual results vary, and no treatment guarantees a specific outcome.

A separate head-to-head trial, SURMOUNT-5, compared tirzepatide directly against semaglutide 2.4mg over 72 weeks. Tirzepatide produced greater average weight reduction. NICE reviewed this evidence when issuing its guidance on tirzepatide (TA1026) and noted that indirect comparisons also favour tirzepatide, while acknowledging the evidence base continues to grow.

For context on how the weekly injection compares to the newer tablet option, the Mounjaro weight loss pill page covers the oral route. And if you are curious about how outcomes differ across the dose schedule, our eight-week weight loss page looks at early progress specifically.

Who does the UK licence actually cover, and what does a prescriber assess?

The licensed population for Mounjaro in weight management is adults with a BMI of 30 or above, or adults with a BMI of 27 or above who have at least one weight-related condition, such as type 2 diabetes, high blood pressure, high cholesterol, or obstructive sleep apnoea. For people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, UK guidance applies thresholds that are 2.5 kg/m² lower.

A BMI that meets the threshold is a starting point, not a decision. A prescriber reviews the full clinical picture: other medicines you take, your history of certain conditions (pancreatitis and specific thyroid conditions are relevant contraindications), whether you are pregnant, breastfeeding, or hoping to conceive in the near future. Mounjaro is not licensed for under-18s, and is not recommended in pregnancy or whilst breastfeeding.

At nume, that assessment is carried out personally by a GPhC-registered Independent Prescriber, a real clinician reading your consultation, not software making an automated call. You can read about our clinical approach on the clinical team page. The full Mounjaro overview covers the complete eligibility picture if you want more detail.

What side effects should you know about, and when does medical help matter?

The most common side effects of Mounjaro are gastrointestinal: nausea, loose stools, constipation, indigestion, and burping. These are typically most noticeable after starting or after a dose step-up, and they settle for most people within days to a couple of weeks. Fatigue, headache, and mild injection-site reactions also appear in the clinical data.

One side effect that deserves specific attention: acute pancreatitis. In January 2026, the MHRA issued a Drug Safety Update confirming that severe, persistent stomach pain (particularly if it spreads toward the back, with or without vomiting) requires urgent medical attention. It is an infrequent but serious risk across this class of medicine. If that symptom pattern develops, stop and seek help the same day rather than waiting for your next appointment.

Patients and prescribers can report suspected side effects using the MHRA's Yellow Card scheme. It takes a few minutes and genuinely contributes to ongoing safety surveillance for newer medicines like Mounjaro.

The pen itself (a pre-filled KwikPen containing four weekly doses) arrives by DPD in plain, unbranded packaging with tracking sent to your phone. Each pen is stored in the fridge. Beyond that, if you want a fuller picture of how Mounjaro affects weight across the dose schedule, that page sets out what the data shows at each stage; your prescriber's guidance and the Patient Information Leaflet included with your treatment are always the definitive source on the practical detail.

If you are ready to check whether treatment is right for you, our free consultation is where to start, reviewed the same day by a named prescriber, and the weight loss jab Mounjaro page is a good place to read about the injection itself before you begin.